136 Notes to the financial statements 28 Pensions and other post-employment benefits continued Sensitivity analysis Effect of changes in assumptions used on the annual defined benefit pension and post-retirement costs or the benefit obligations: m A 0.25% decrease in discount rate would have the following approximate effect: Increase in annual pension cost 7 Increase in annual post-retirement benefits cost Increase in pension obligation 440 Increase in post-retirement benefits obligation 36 A one year increase in life expectancy would have the following approximate effect: Increase in annual pension cost 24 Increase in annual post-retirement benefits cost 7 Increase in pension obligation 249 Increase in post-retirement benefits obligation 49 A 0.25% decrease in expected rates of returns on assets would have the following approximate effect: Increase in annual pension cost 24 A 1% increase in the rate of future healthcare inflation would have the following approximate effect: Increase in annual post-retirement benefits cost 2 Increase in post-retirement benefits obligation 45 A 0.25% increase in inflation would have the following approximate effect: Increase in annual pension cost 24 Increase in pension obligation 316 29 Other provisions Integration Legal Major Employee and and other restructuring related manufacturing Other disputes programmes provisions re-organisation provisions Total m m m m m m At 1st January 2009 1,903 652 268 90 186 3,099 Exchange adjustments 211 33 20 5 17 286 Charge for the year 667 487 57 1 32 1,244 Reversed unused 86 15 4 7 13 125 Unwinding of discount 1 3 7 11 Utilised 254 450 69 21 26 820 Acquisition of subsidiary 17 17 Transfer to pensions obligations 72 72 Reclassifications and other movements 2 9 3 165 173 At 31st December 2009 2,020 574 241 55 351 3,241 To be settled within one year 1,717 399 31 7 102 2,256 To be settled after one year 303 175 210 48 249 985 At 31st December 2009 2,020 574 241 55 351 3,241 GSK Annual Report 2009 Financial statements P91P182 Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 137 Notes to the financial statements Employee related provisions 29 Other provisions continued Employee related provisions includes the exchange offer incentive Legal and other disputes programme which operated at the time of the merger to GSK is involved in a number of legal and other disputes, including encourage staff to convert Glaxo Wellcome or SmithKline Beecham notification of possible claims, as set out in Note 44 Legal share options into GlaxoSmithKline share options.
Provisions for legal and other disputes include paid either when employees exercise the relevant options, or when amounts relating to US anti-trust, product liability, contract the options lapse, up to 2010.
There is no impact of discounting terminations, self-insurance, environmental clean-up and on this provision in 2009 2008 nil, which was calculated using property rental.
The Group also provides certain medical benefits to disabled employees and their spouses in the USA.
The discount on these provisions increased by 5 million in At 31st December 2009, the provision for these benefits 2009 2008 61 million decrease and was calculated using amounted to 118 million.
Other employee benefits reflect a risk-adjusted projected cash flows and risk-free rates of return.
variety of provisions for severance costs, jubilee awards and other The movement in 2009 includes an increase of 6 million long-service benefits.
arising from a change in the discount rate in the year.
Certain products have a history of claims made and settlements which Integration and manufacturing re-organisation makes it possible to use an IBNR incurred but not reported Provisions for integration and manufacturing re-organisations actuarial technique to determine a reasonable estimate of the reflect costs related to ongoing restructuring programmes Groups exposure for unasserted claims in relation to those not included within the costs disclosed in Note 7, Major products.
Apart from the IBNR provision, no provisions have been restructuring programmes.
The ultimate liability for such matters may vary from the amounts provided and is dependent upon the Other provisions outcome of litigation proceedings, investigations and possible The Group has recognised contingent consideration in respect of settlement negotiations.
the acquisitions of Bristol Myers Squibb Pakistan Private Limited and Stiefel Laboratories, Inc. as described in Note 38 Acquisitions It is in the nature of the Groups business that a number of and disposals.
The contingent consideration is payable upon these matters, including those provided using the IBNR actuarial certain criteria being met by certain specified dates in the future.
technique, may be the subject of negotiation and litigation over The initial recognition of these provisions are included within several years.
The largest individual amounts provided are expected reclassifications and other movements.
The aggregate provision to be settled within three years.
for these items amounts to 161 million at 31st December 2009.
At 31st December 2009, it is expected that 97 million 2008 112 million of the provision made for legal and other disputes will be reimbursed by third party insurers.
This amount is included within other receivables in Note 22, Other non-current assets and Note 24, Trade and other receivables.
For a discussion of legal issues, see Note 44 Legal proceedings.
Major restructuring programmes In October 2007 GSK announced a significant new Operational Excellence programme to improve the effectiveness and productivity of its operations see Note 7 Major restructuring programme.
A significant expansion of the Operational Excellence programme was approved by the Board and announced in February 2009.
A further expansion was approved by the Board and announced in February 2010.
Provisions for staff severance payments are made when management has made a formal decision to eliminate certain positions and this has been communicated to the groups of employees affected.
No provision is made for staff severance payments that are made immediately.
Pension augmentations arising from staff redundancies of 72 million have been charged during the year and then transferred to the pension obligations provision as shown in Note 28 Pensions and other post-employment benefits.
Asset write-downs have been recognised as impairments of property, plant and equipment in Note 17 Property, plant and equipment.
